What is Chematics?
Founded in 1988, Chematics has carved out a specialized niche in the health diagnostics market by providing accessible testing tools for alcohol, glucose, and cholesterol monitoring. By focusing on user-friendly products like the Alco-Screen and Chemcard lines, the company serves a diverse ecosystem ranging from clinical physician offices to home-based health management. Their business model prioritizes the democratization of early detection, ensuring that high-quality diagnostic data is available at an affordable price point. As a US-based manufacturer, Chematics maintains a competitive edge through rigorous quality control and a deep understanding of the regulatory landscape governing point-of-care diagnostics.
How much funding has Chematics raised?
Chematics has raised a total of $110K across 1 funding round:
Debt
$110K
Debt (2021): $110K with participation from PPP
Key Investors in Chematics
PPP
Public-Private Partnership
What's next for Chematics?
With this late-stage capital, Chematics is well-positioned to scale its distribution networks and potentially accelerate the development of next-generation diagnostic assays. The strategic allocation of these funds will likely focus on optimizing supply chain efficiencies and expanding market penetration for its core product lines. As the healthcare industry continues to shift toward decentralized testing and patient-centric care, Chematics is poised to leverage its decades of expertise to capture additional market share. Future growth will likely be driven by the integration of digital health interfaces with their existing physical testing hardware, further cementing their role as a critical provider in the preventative medicine value chain.
See full Chematics company page
